

[illegible]

PATENT
Application No.: 09/821,255
ATTORNEY DOCKET NO.: TNX 98-2-01
CUSTOMER NO: 26839

**MARKED-UP
VERSION OF
SUBSTITUTE
PAGES
FOR
SPECIFICATION**

09821255.072701

irrelevant isotype-matched control MAb G3-519. The Y-axis represents the % hemolysis inhibition. The X-axis represents the concentration of factor D.

Fig. 6 shows the inhibition of factor-D dependent EAC3b cell lysis by MAb 166-32. The alternative C3 convertase was assembled on EAC3b cells by incubation with factor B, factor P and factor D. Different concentrations of MAb 166-32 were added to the [] incubation buffer to inhibit the activity of factor D. The line marked with filled squares represents MAb 166-32. The line marked with filled circles represents MAb G3-519. The Y-axis represents the % hemolysis inhibition. The X-axis represents the concentration of the MAbs.

Fig. 7 shows the inhibition of C3a production from zymosan by MAb 166-32. Zymosan activated the alternative complement pathway in the presence of human serum. The production of C3a was measured by using an ELISA assay kit. The line marked with filled squares represents MAb 166-32. The line marked with filled circles represents the irrelevant isotype-control MAb G3-519. The Y-axis represents the % inhibition of C3a production. The X-axis represents the concentration of the MAbs.

Fig. 8 shows the inhibition of sC5b-9 production from zymosan by MAb 166-32. Zymosan activated the alternative complement pathway in the presence of human serum. The production of sC5b-9 was measured by using an ELISA assay kit. The line marked with filled squares represents MAb 166-32. The line marked with filled circles represents the irrelevant isotype-control MAb G3-519. The Y-axis

Fig. 37 shows that MAb 166-32 (closed squares) inhibits the production of platelet thrombospondin in the extracorporeal circuits as compared to the negative control MAb G3-519 (open squares). The number of paired circuits is 5. Mean \pm S.E.M.; $P = 0.016$ (*), $P = 0.003$ (**) and $P = 0.0001$ (***) by two-way ANOVA.

5 Fig. 38 shows that MAb 166-32 (closed squares) inhibits the production of IL-8 in the extracorporeal circuits as compared to the negative control MAb G3-519 (open squares). The number of paired circuits is 5. Mean \pm S.E.M.; $P = 0.0001$ (*) by two-way ANOVA.

10 Fig. 39 shows the pharmacokinetics of [Mab] MAb 166-32 in a baboon model of cardiopulmonary bypass (CPB).

Fig. 40 shows the inhibition of alternative complement activation by [Mab] MAb 166-32 in baboon CPB.

Fig. 41 shows the Bb concentration as affected by [Mab] MAb 166-32.

Fig. 42 shows the C4d concentration as affected by [Mab] MAb 166-32.

15 Fig. 43 shows the C3a concentration as affected by [Mab] MAb 166-32.

Fig. 44 shows CD11b expression on neutrophils as affected by [Mab] MAb 166-32.

Fig. 45 shows CD11b expression on monocytes as affected by [Mab] MAb 166-32.

Fig. 46 shows CD62P expression on platelets as affected by [Mab] MAb 166-32.

Fig. 47 shows plasma IL-6 levels as affected by [Mab] MAb 166-32.

20 Fig. 48 shows plasma LDH levels as affected by [Mab] MAb 166-32.

Fig. 49 shows plasma creatine kinase (CK) levels as affected by [Mab] MAb 166-32.

Fig. 50 shows plasma creatine kinase (CK-MB) levels as affected by [Mab] MAB 166-32.

Fig. 51 shows plasma creatinine levels as affected by [Mab] MAB 166-32.

Fig. 52 shows dynamic lung compliance of baboons in CPB as affected by [Mab]

5 MAB 166-32.

DESCRIPTION OF THE SEQUENCE LISTING

SEQ ID NO:1 shows the nucleotide sequence of human factor D.

SEQ ID NO:2 shows the amino acid sequence of human factor D.

SEQ ID NO:3 shows the nucleotide sequence of pig factor D.

10 SEQ ID NO:4 shows the amino acid sequence of pig factor D.

SEQ ID NO:5 is the primer used for cloning the V_K gene of MAb 166-32.

SEQ ID NO:6 was used as an annealed adaptor for cloning the V_K gene of MAb 166-32, as described below, and as a primer.

15 SEQ ID NO:7 was also used as an annealed adaptor for cloning the V_K gene of MAb 166-32, as described below.

SEQ ID NO:8 was used as a 3' primer for cloning the V_H gene of MAb 166-32, as described below.

SEQ ID NO:9 was a primer used for cloning the V_H gene of MAb 166-32.

SEQ ID NO:10 was used as a primer for cloning the V_H gene of MAb 166-32.

20 SEQ ID NO:11 was the 5' primer for the PCR of the Fd gene of MAb 166-32.

SEQ ID NO:12 was the 3' primer for the PCR of the Fd gene of MAb 166-32.

SEQ ID NO: 13 was the 5' primer for the Fd gene PCR of MAb 166-32

00001255-072701

The blank contained no antibody; only the plain medium and the serum. After incubation, 50 μ l of washed zymosan suspension were added to each tube for incubation for 30 minutes at 37°C. The microtubes were then centrifuged at 2000 x g for 5 minutes, the supernatants were collected and mixed with equal volume of Specimen Stabilizing Solution (Quidel, San Diego, CA). The samples were frozen at -25°C until being assayed. The concentration of C3a and sC5b-9 in the samples were measured by quantitative ELISA kits (Quidel) according to the procedures provided by the manufacturer.

Fig. 7 shows that MAb 166-32 inhibits the generation of C3a from complement-activated zymosan, whereas the irrelevant MAb G3-519 has no effect. These data suggest that MAb 166-32 inhibits the formation of C3 convertase by factor D. The complete inhibition of factor D by MAb 166-32 can effectively block the formation of C3 convertase, as indicated by the inability to generate C3a. This will lead to the inhibition of C5 convertase in the subsequent steps of the complement cascade, as evidenced by the inhibition of sC5b-9 (MAC) formation (Fig. 8).

Example 6: Inhibition of complement-activated hemolysis by the Fab of MAb 166-32

In order to examine whether the monovalent form of MAb 166-32 is as effective in inhibiting the alternative complement pathway as the parental bivalent MAb[]166-32, the Fab of MAb 166-32 was prepared by papain digestion using a commercial reagent kit (Pierce). The Fab was then tested for inhibitory activity on the alternative

5
10

10

15

20

Fig. 10 shows that MAb 166-32 has strong inhibitory activity against sera from human, rhesus monkey, baboons, cynomolgus monkey and chimpanzee and

moderate inhibitory activity against sera from [baboon, cynomolgus monkey,] sheep and dog. The antibody does not inhibit sera from mouse, hamster, rat, rabbit, guinea pig and pig. These data suggests that MAb 166-32 binds to an epitope on factor D shared by humans, rhesus monkeys, chimpanzees, baboons, cynomolgus monkeys, sheep and dogs.

Example 8: Construction of human Factor D mutants for epitope mapping of MAb 166-32

To delineate the binding epitope on human factor D recognized by MAb 166-32, the reactivity of the antibody with human factor D on Western blots was first tested. MAb 166-32 did not react with SDS-denatured human factor D (either reduced or non-reduced) immobilized on nitrocellulose membrane. This result indicates the MAb 166-32 binds native but not denatured factor D.

Since MAb 166-32 does not inhibit the hemolytic activity of mouse and pig factor D as described in Example 7, it is likely that MAb 166-32 binds to a site on human factor D that has a high degree of difference in the amino acid sequence from those of mouse and pig factor D. Based on this concept, various factor D mutants and hybrids were made by replacing amino acid residues in human factor D with the corresponding amino acid residues in the pig counterpart, for mapping the binding epitope of Mab 166-32, as described below.

(1) Construction of factor D mutants and hybrids

Human factor D gene segments were obtained by polymerase chain reaction (PCR) using human adipocyte cDNA (Clontech, San Francisco, CA) as the template

temperature. After the wells were washed, peroxidase substrate solution was added for color development and OD450 was measured as described above. Purified thrombospondin (Calbiochem) was used as for a calibration standard in the assay.

IL-8 was measured by an ELISA kit (R & D Systems). IL-8, a proinflammatory cytokine, is produced by neutrophils, monocytes/macrophages, and T cells upon activation by anaphylatoxins.

The data from 5 paired circuits were statistically analyzed using 2-way ANOVA of factorial, randomized block design for all assays except hemolytic assays which used a paired T-test for analysis (see pg. 11 And Figure 26). The data were represented as mean \pm standard error.

(2) Results and conclusions

MAb 166-32 at 18 $\mu\text{g/ml}$ inhibited completely the alternative complement activity measured by a hemolytic assay using unsensitized rabbit RBCs, whereas the negative control Mab G3-519 had no effect (Fig. 26). On the other hand, MAb 166-32 did not inhibit the classical pathway hemolysis of sensitized sheep RBCs. The selective inhibition of the alternative complement pathway is in agreement with the complete inhibition of the production of Bb (Fig. 27). Bb is the enzymatic product of factor B activation specific to the alternative complement pathway. On the other hand, there was an increase in the plasma concentration of C4d in both circuits treated with either MAb 166-32 or G3-519 (Fig. 28). C4d is a specific marker for activation of the classical complement pathway.

measurement of area at risk and infarct size, respectively. Coronary lymph and whole blood from the jugular vein were collected before ischemia and at the end of the experiment. These samples were used to measure the concentration of the injected antibodies and alternative pathway hemolytic activity.

5 The results show that the highest achievable concentration of MAb 166-32 in the coronary lymph was about 30 µg/ml, which is well below the concentration required for complete inhibition of dog factor D in the coronary circulation. The antibody was also detected in the systemic circulation, suggesting that the injected antibody dissipated outside of the heart. The data from the hemolytic assays show
10 that alternative complement activity was not reduced; as is consistent with the fact that the concentration of the antibody was low. Therefore, it is not possible to draw a conclusion on the effect of MAb 166-32 in reperfusion from these experiments in dogs.

15 Example 14: Effects of [Mab] MAb 166-32 in Baboons Undergoing
Cardiopulmonary Bypass

Anti-factor D [Mab] MAB 166-32 (murine antibody) was studied in a baboon model of hypothermic cardiopulmonary bypass (CPB) for pharmacokinetics and for its inhibitory effects on complement, neutrophils, monocytes, platelets, and tissue injury. Baboons was selected as the animal model because they have been extensively used as a non-human primate model in CPB studies (Hiramatsu Y et al., J. Lab. Clin. Med. 1997; 130: 412-420;

Gikakis N et al., J. Thorac. Cardiovasc. Surg. 1998; 116: 1043-1051) and [Mab] MAB 166-32 is equally effective at inhibiting baboon factor D and human factor D.

Fourteen healthy adult baboons (ca. 15 kg of body weight) were used in the study. The baboons were pre-screened for negative serological reactivity with [Mab] MAB 166-32 by ELISA. The baboons were assigned to two groups: 7 in the [Mab] MAB 166-32-treated group and 7 in a saline-control group. Baboons in the treatment group received a single intravenous bolus injection of [Mab] MAB 166-32 at 5 mg/kg, whereas baboons in the control group received an equal volume of saline. This dosage of [Mab] MAB 166-32 was chosen because it was estimated to be adequate to completely neutralize the factor D for about 7 hours, based on previously obtained data that [Mab] MAB 166-32 at 1 mg/kg completely inhibited factor D in rhesus monkeys for at least 1.5 hours. [Mab] MAB 166-32 inhibited baboon, monkey and human factor D equally well.

Baboons were sedated with an intramuscular injection of 10 mg/kg of ketamine hydrochloride, and anesthesia was induced with 5 mg/kg of thiopental sodium. The animals were then intubated, and general anesthesia was maintained with inhaled isoflurane.

Heparin (300 units/kg) was administered for anti-coagulation. After a median sternotomy was performed, the ascending aorta and the right atrium were cannulated with a 14-French aortic cannular (DLP, Inc. Grand Rapids, MI,

5

10

20

of [Mab] MAB 166-32 or saline (at 45 minutes), before CPB (at 1 hour), 10 minutes in CPB at 37°C, 25 minutes in CPB at 27°C, 85 minutes in CPB at 27°C, 105 minutes in CPB at 37°C after re-warming, 135 minutes in CPB at 37°C prior to protamine administration (at 3.25 hours), 30 minutes after CPB at 37°C, 1
 5 hour after CPB at 37°C, 2 hours after CPB at 37°C, 6 hours after CPB at 37°C (at 9.25 hours), and finally 18 hours after CPB at 37°C (at 21.25 hours).

Experiments with 8 of the 14 baboons (4 in the treatment group and 4 in the control group) were terminated at 6 hours after CPB, whereas the remaining animals (3 in the treatment group and 3 in the control group) were terminated 18
 10 hours after CPB.

Plasma and whole blood samples were used in different assays to measure:

(1) Plasma concentration of free [Mab] MAB 166-32 by ELISA using factor D as the coating antigen;

(2) Functional activity of factor D in baboon plasma as determined by two
 15 hemolytic assays: rabbit red blood cells for the alternative complement pathway and sensitized chicken red blood cells for the classical complement pathway ;

(3) Plasma concentration of complement Bb, C4d, and C3a by ELISA (Quidel Corp., San Diego, CA, USA);

20 (4) Expression level of CD11b on neutrophils and monocytes by immunofluorocytometric methods;

0001255-072701

- (5) Expression level of CD62P on platelets by immunofluorocytometric methods;
 (6) Plasma concentration of IL-6 by ELISA (BioSource International, Inc.,
 Camarillo, CA, USA); and
 (7) Plasma concentration of lactate dehydrogenase (LDH), creatine kinase (CK),
 creatine kinase MB isoenzymes (CK-MB), and creatinine.

The data were analyzed statistically by student's T-test (for C4d) and 2-way ANOVA of repeated measurements (for other parameters) (significant at $p < 0.05$). The data were represented as mean \pm SEM.

(II) Results and Discussion

In this study, baboons were treated with a single intravenous bolus injection of 5 mg/kg of [Mab] MAB 166-32. The plasma concentrations of the free antibody were measured by an ELISA using human factor D as coating antigen (Fig. 39). At 45 minutes after the antibody injection, the plasma concentration of free [Mab] MAB 166-32 was 68.3 ± 9.9 $\mu\text{g/ml}$. The antibody concentration then decreased to 23.4 ± 4.4 $\mu\text{g/ml}$ at 10 minutes after CPB, as a result of hemodilution upon the initiation of CPB. The antibody concentration remained at 10–13 $\mu\text{g/ml}$ until 3 hours after CPB. The antibody concentration reduced to 6.2 ± 2.3 $\mu\text{g/ml}$ at 6 hours after CPB and to 1.7 ± 3.9 $\mu\text{g/ml}$ at 18 hours after CPB.

Using an alternative complement hemolytic assay with rabbit red blood cells, the functional activity of factor D in the plasma samples from the [Mab] MAB 166-32 treated animals was measured (Fig. 40). The alternative

5

15

20

the baseline (Fig. 42). However, there was an increase of C4d in both animal groups after neutralization of heparin with protamine at the end of the CPB, indicating the activation of the classical pathway as reported earlier in other studies (Kirklin JK et al., Ann. Thorac. Surg. 1986; 41: 193-199; Carr JA et al., J. Cardiovasc. Surg. (Torino) 1999; 40: 659-666).

Activation of complement is shown by an increase in plasma C3a in the control animals (Fig. 43). In contrast, animals treated with [Mab] MAB 166-32 show almost complete inhibition of C3a production. A slight increase of C3a level is observed in the [Mab] MAB 166-32 treated animals after neutralization of heparin with protamine. Together, the results from Figs. 41, 42 and 43 support the notion that complement activation during CPB is predominantly via the alternative complement pathway. Due to the lack of cross-reactivity of the reagents in the commercial ELISA kits for baboon C5a and sC5b-9 (Quidel and Becton Dickinson, respectively), their concentrations were not determined.

Activation of neutrophils and monocytes in the baboons was examined by measuring CD11b (α -integrin) expression using immunofluorocytometric methods. In the control animals, the CD11b expression on neutrophils increased rapidly and reached the maximum at about 85 minutes after the start of CPB ($209 \pm 42.9\%$ of the baseline) (Fig. 44). It then declined slowly back to around the baseline. In contrast, the increase of CD11b expression on neutrophils in the [Mab] MAB 166-32 treated animals was delayed and smaller in magnitude (Fig.

44). The maximum level of CD11b expression was $129.3\% \pm 5.5\%$ of the baseline. Inhibition of the increase in CD11b expression on monocytes from the [Mab] MAB 166-32 treated animals was also observed (Fig. 45).

Activation of platelets in the baboons was examined by measuring CD62P (P-selectin) expression using immunofluorocytometric methods. Both the control and [Mab] MAB 166-32 treated animals show a similar pattern of inhibition of CD62P expression (Fig. 46). The exact cause of the inhibition of CD62P expression is unclear.

The effect of [Mab] MAB 166-32 treatment on pro-inflammatory cytokines was also examined. Baboons treated with [Mab] MAB 166-32 had a significantly smaller increase in plasma IL-6 concentration as compared to the control animals (Fig. 47).

The effects of [Mab] MAB 166-32 treatment on tissue injury of various organs were also studied. The increase of plasma LDH levels was significantly reduced in the [Mab] MAB 166-32 treated animals at 3 and 6 hours after CPB (Fig. 48). This indicates protection against tissue injury. Specifically for myocardial injury, the increase of both plasma CK and CK-MB levels at 6 and 18 hours after CPB was significantly lower in the [Mab] MAB 166-32 treated animals as compared to the control animals (Figs. 49 and 50).

0001255-072701

The renal function of the baboons was also examined. A reduction in the increase of plasma creatinine was found in the baboons treated with [Mab] MAb 166-32 as compared to the control animals at 18 hours after CPB (Fig. 52).

As for pulmonary functions, the dynamic lung compliance of the [Mab] MAb 166-32 treated animals was higher than that of the control animals during the early phase of the open-chest surgery (Fig. 51). However, there was no significant difference in the lung compliance between the two groups of animals during and after CPB. The initial increase of the dynamic lung compliance in the control animals is probably attributed to the open-chest procedure. The higher dynamic lung compliance in the [Mab] MAb 166-32 treated animals could be due to the protection against surgical trauma which was shown to be associated with complement activation via the alternative complement pathway. (Gu YJ et al., Chest 1999; 116: 892-898).

The renal function of the baboons was also examined. A reduction in the increase of plasma creatinine was found in the baboons treated with [Mab] MAb 166-32 as compared to the control animals at 18 hours after CPB (Fig. 52).

In conclusion, anti-factor D [Mab] MAb 166-32 is effective in inhibiting the activation of the alternative complement pathway in a baboon model of CPB. Inhibition of the alternative complement pathway by [Mab] MAb 166-32 effectively reduces the activation of neutrophils and monocytes, as well as the production of IL6. Treatment with [Mab] MAb 166-32 confers protection against

00021265-072701

myocardial and renal injury. The alternative complement pathway may play a predominant role in the inflammation and tissue injury caused by extracorporeal circulation, surgical trauma and ischemia/reperfusion. Therefore [Mab] MAb 166-32 could be potentially useful for the treatment of systemic inflammatory

5 response syndromes in CPB.

The foregoing description, terms, expressions and examples are exemplary only and not limiting. The invention includes all equivalents of the foregoing embodiments, both known and unknown. The invention is limited only by the claims which follow and not by any statement in any other portion of this document or in

10 any other source.

00011555-072701